Survival outcomes and toxicity profile after CT-guided HDR brachytherapy (interventional radiotherapy) for liver oligometastases in breast cancer patients: The BRALIBREST real world multicenter study

This is the authors' abstract. We don't add key points for this paper.

OBJECTIVE: To evaluate efficacy and tolerability of high-dose-rate brachytherapy (HDR-BT) for breast-cancer (BC) liver oligometastases. STUDY DESIGN: We included patients with oligometastatic breast cancer, defined as having ≤ 5 liver metastases, WHO performance status <3, tumor diameter <10 cm. Patients were excluded if tumor location prevented applicator placement or adequate dosing of CT-guided HDR-BT. End-points were overall survival (OS), progression-free survival (PFS), locoregional control (LRC), modified PFS (mPFS), freedom from subsequent systemic-therapy line and radiological response - disease control rate and objective response rate (ORR). Univariate (UVA) and multivariate (MVA) Cox models explored clinicopathologic and dosimetric predictors. Delivering ≥25 Gy to 90 % of GTV halved the risk of death. Only grade 1-2 acute toxicities were observed; no grade ≥3 events, with 8 % late grade 3 hepatic toxicity. CONCLUSION: HDR-BT appears to be an effective metastasis-directed therapy for selected patients with BC liver oligometastases.